ELCC 2022

Early-Stage Non-Small Cell Lung Cancer

Real-world treatment and survival in early-stage NSCLC

Presented By

Dr Howard West, City of Hope Comprehensive Cancer Center, CA, USA

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:44

Consistent efficacy of osimertinib in Chinese and global population

Presented By

Dr Jie Wang, Beijing Cancer Hospital, China

Trial

Phase 3, ADAURA

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:43

Promising efficacy of neoadjuvant osimertinib in EGFR-mutated NSCLC

Presented By

Dr Chao Lyu, Beijing Cancer Hospital, China

Trial

Phase 2, NEOS

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:43

Peri-operative survival in bilobectomy is comparable with that of left pneumonectomy

Presented By

Dr Andrew Li, Yale School of Medicine, CT, USA

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:42

Advanced Non-Small Cell Lung Cancer

Pro-inflammatory tumour profile predicts complete pathological response to neoadjuvant chemoimmunotherapy

Presented By

Dr Marta Casarrubios, Hospital Puerta de Hierro-Majadahonda, Spain

Trial

Phase 2, NADIM

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:41

Furmonertinib outperforms gefitinib as first-line therapy in patients with EGFR-mutated NSCLC

Presented By

Dr Yuankai Shi, National Cancer Center, China

Trial

Phase 3, FURLONG

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:41

Second-line oritinib demonstrated potential clinical benefit in advanced EGFR-mutated NSCLC

Presented By

Prof. Caicun Zhou, Shanghai Pulmonary Hospital, China

Trial

Phase 2

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:40

Updated results confirm efficacy and safety of entrectinib in patients with NTRK fusion-positive NSCLC

Presented By

Prof. Byoung Chul Cho, Yonsei Cancer Center Seoul, South Korea

Trial

Phase 1/2, ALKA-372-001, STARTRK-1, STARTRK-2

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:40

ROS1 rearrangement-targeting unecritinib is a potential new first-line strategy

Presented By

Dr Shun Lu, Shanghai Chest Hospital, China

Trial

Phase 2

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:40

Savolitinib is effective in patients with MET-mutated NSCLC

Presented By

Dr Shun Lu, Shanghai Chest Hospital, China

Trial

Phase 2

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:39

Sintilimab plus chemotherapy improves OS in treatment-naïve, stage III–IV non-squamous NSCLC

Presented By

Dr Yunpeng Yang, Sun Yat-sen University Cancer Center, China

Trial

Phase 3, ORIENT-11

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:39

Updated results of CameL-sq trial confirm benefit of camrelizumab

Presented By

Prof. Caicun Zhou, Shanghai Pulmonary Hospital, China

Trial

Phase 3, CameL-sq

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:38

No long-term benefit of adding ipilimumab to pembrolizumab in metastatic NSCLC

Presented By

Dr Delvys Rodriguez-Abreu, Universidad de Las Palmas de Gran Canaria, Spain

Trial

Phase 3, KEYNOTE-598

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:38

In concurrent CRT for stage III, unresectable NSCLC, performance status is better with proton therapy than photon therapy

Presented By

Dr Francesco Cortiula, Maastricht University Medical Center, the Netherlands

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:37

No improved prognosis for concurrent versus sequential immune checkpoint inhibition and CRT in unresectable NSCLC

Presented By

Dr Lukas Käsmann, University Hospital Munich, Germany

Trial

Phase 3

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:37

Durvalumab after sequential CRT safe in stage III, unresectable NSCLC

Presented By

Dr Marina Garassino, University of Chicago, IL, USA

Trial

Phase 2, PACIFIC-6

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:37

No impact of grade ≥2 pneumonitis on patient-reported outcomes in PACIFIC

Presented By

Prof. Rina Hui, University of Sydney, Australia

Trial

Phase 3, PACIFIC

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:37

Immunotherapy delays deterioration in health-related quality of life in metastatic NSCLC

Presented By

Dr Edward Garon, David Geffen School of Medicine at UCLA, CA, USA

Trial

Phase 3, POSEIDON

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:36

Small Cell Lung Cancer

Total metabolic tumour volume: a new potential prognostic factor in SCLC

Presented By

Dr Elisa Andrini, Sant'Orsola-Malpighi University Hospital, Italy

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:34

Radiation dose on oesophagus predicts OS in SCLC patients treated with chemoradiotherapy

Presented By

Dr Bilal Tahir, University of Sheffield, United Kingdom

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:34

Characteristics of long-term survivors in the CASPIAN trial

Presented By

Dr Niels Reinmuth, Asklepios Lung Clinic, Germany

Trial

Phase 3, CASPIAN

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:34

Outcomes of real-world CANTABRICO trial match results from CASPIAN

Presented By

Dr Dolores Isla, Hospital Clinico Universitario Lozano Blesa, Spain

Trial

CANTABRICO

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:33

Lung Cancer Epidemiology